moxifloxacin has been researched along with pomalidomide in 1 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (pomalidomide) | Trials (pomalidomide) | Recent Studies (post-2010) (pomalidomide) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 623 | 121 | 552 |
| Protein | Taxonomy | moxifloxacin (IC50) | pomalidomide (IC50) |
|---|---|---|---|
| DNA damage-binding protein 1 | Homo sapiens (human) | 2.1 | |
| Protein cereblon | Homo sapiens (human) | 1.85 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Assaf, M; Liu, L; Mondal, SA; O'Mara, E | 1 |
1 trial(s) available for moxifloxacin and pomalidomide
| Article | Year |
|---|---|
A Phase 1, double-blind, 4-period crossover study to investigate the effects of pomalidomide on QT interval in healthy male subjects.
Topics: Adult; Angiogenesis Inhibitors; Anti-Bacterial Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Fluoroquinolones; Healthy Volunteers; Heart Conduction System; Heart Rate; Humans; Male; Moxifloxacin; Thalidomide; Treatment Outcome | 2016 |